Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib

被引:21
作者
Chen, Fengsheng [1 ]
Luo, Xi [1 ]
Zhang, Jinbiao [1 ]
Lu, Yang [1 ,2 ]
Luo, Rongcheng [1 ]
机构
[1] So Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, Nucl Med Serv, New York, NY 10065 USA
关键词
Tissue polypeptide-specific antigen; Cytokeratin-19-fragments; Gefitinib; Non-small-cell lung cancer; Prognostic factor; GROWTH-FACTOR RECEPTOR; TUMOR-MARKERS; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY REGIMENS; RANDOMIZED-TRIAL; SUPPORTIVE CARE; EGFR MUTATIONS; THERAPY; SURVIVAL; PLATINUM;
D O I
10.1007/s12032-009-9315-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Serum concentrations of tissue polypeptide-specific antigen (TPS) and Cytokeratin-19-Fragments (CYFRA 21-1) before operation or chemotherapy have been proved to be a useful prognostic tool for patients with NSCLC, but the related data for advanced NSCLC patients treated with gefitinib are limited. We retrospectively reviewed 122 advanced NSCLC patients treated with gefitinib between April 2002 and August 2007. Multiple clinical factors including pretreatment serum levels of TPS and CYFRA 21-1, age, gender, performance status (PS), smoking history, stage, histology, the number of prior chemotherapy and the patients' clinical outcomes were analyzed. Patients without elevated serum TPS levels had a more RR (36.8%) than those with elevated serum TPS levels (18.5%) (P = 0.023), nevertheless, a similar result was not seen in patients with normal CYFRA 21-1 levels. For patients with normal vs. high TPS levels, the median survival times (MSTs) were 15.9 vs. 7.3 months (P = 0.001). For patients with normal vs. high CYFRA 21-1, the MSTs were 15.4 vs. 7.5 months (P = 0.003). Moreover, for patients with both elevated, vs. one elevated and both normal TPS and CYFRA 21-1 levels, the MSTs were 5.4 vs. 11.4 months (P = 0.001), and 16.5 months (P < 0.001), respectively. In multivariate analysis, TPS (P = 0.001) and CYFRA 21-1 (P = 0.005) alone or combination (P < 0.001) remained significant correlation to survival. In NSCLC patients with gefitinib therapy, pretreatment serum levels of TPS and CYFRA 21-1 alone or combined might be independent prognostic factors, and the pretreatment serum TPS level may predict the tumor response.
引用
收藏
页码:950 / 957
页数:8
相关论文
共 45 条
[1]   Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer [J].
Ardizzoni, Andrea ;
Cafferata, Mara A. ;
Tiseo, Marcello ;
Filiberti, Rosangela ;
Marroni, Paola ;
Grossi, Francesco ;
Paganuzzi, Michela .
CANCER, 2006, 107 (12) :2842-2849
[2]   Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Non-Small-Cell Lung Cancer [J].
Bai, Hua ;
Mao, Li ;
Wang, Hang Shu ;
Zhao, Jun ;
Yang, Lu ;
An, Tong Tong ;
Wang, Xin ;
Duan, Chun Jian ;
Wu, Na Mei ;
Guo, Zhi Qing ;
Liu, Yi Xu ;
Liu, Hong Ning ;
Wang, Ye Yu ;
Wang, Jie .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2653-2659
[3]   Clinical utility of cytokeratins as tumor markers [J].
Barak, V ;
Goike, H ;
Panaretakis, KW ;
Einarsson, R .
CLINICAL BIOCHEMISTRY, 2004, 37 (07) :529-540
[4]  
Barak V, 1997, J TUMOR MARKER ONCOL, V12, P17
[5]  
BARAK V, 1994, J TUMOR MARKER ONCOL, V8, P89
[6]   CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy [J].
Barlési, F ;
Tchouhadjian, C ;
Doddoli, C ;
Torre, JP ;
Astoul, P ;
Kleisbauer, JP .
BRITISH JOURNAL OF CANCER, 2005, 92 (01) :13-14
[7]   Classification, staging and prognosis of lung cancer [J].
Beadsmoore, CJ ;
Screaton, NJ .
EUROPEAN JOURNAL OF RADIOLOGY, 2003, 45 (01) :8-17
[8]   Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].
Breathnach, OS ;
Freidlin, B ;
Conley, B ;
Green, MR ;
Johnson, DH ;
Gandara, DR ;
O'Connell, M ;
Shepherd, FA ;
Johnson, BE .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742
[9]   Lung tumor markers of cytokeratin origin: an overview [J].
Buccheri, G ;
Ferrigno, D .
LUNG CANCER, 2001, 34 :S65-S69
[10]   Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study [J].
Chang, Alex ;
Parikh, Purvish ;
Thongprasert, Sumitra ;
Tan, Eng Huat ;
Perng, Reury- Perng ;
Ganzon, Domingo ;
Yang, Chih-Hsin ;
Tsao, Chao-Jung ;
Watkins, Claire ;
Botwood, Nick ;
Thatcher, Nick .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) :847-855